Se-cure Pharmaceuticals Ltd. has developed a unique Selective Estrogen Receptor Modulator (SERM) for the management of menopause.

The product is called Femarelle^®; Femarelle^® is a novel SERM that affects estrogen receptors only in specific sites, without affecting tissues where any change can have dangerous consequences.

Clinical and pre-clinical studies have shown that Femarelle^® exerts agonistic (stimulatory) activity on the estrogen receptors that control menopausal symptoms and bone build-up, while having an antagonistic (blocking) effect on estrogen receptors in the breast and the uterus. Furthermore, Femarelle^® was shown not to affect the hormonal blood profile and clotting parameters. Thus, Femarelle^® provides a safe and effective therapeutic option for the management of menopause.

For more information on Femarelle^® and its scientific backup, please visit our website: www.femarelle.com